Drug Profile


Alternative Names: MEDI-507

Latest Information Update: 26 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catholic University of Louvain
  • Developer BioTransplant (CEASED); MedImmune
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Graft-versus-host disease; Psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; T cell lymphoma

Most Recent Events

  • 26 Jun 2007 Discontinued - Phase-I for T-cell lymphoma in USA (IV)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 30 Jun 2006 Siplizumab has been recommended for orphan drug status for T and NK cell neoplasms in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top